GPX2 and breast carcinoma: In fact, GPx2 downregulation is a physiologically relevant change in breast cancer; analysis of a database of 1,809 patients, showed an association of GPx2 mRNA downregulation in luminal B, HER2-enriched, and basal-like tumours with poor patient survival [9].